Trial Profile
PLATINUM: A Prospective, Randomized, Multicenter Trial to Assess an Everolimus-Eluting Coronary Stent System (PROMUS Element) for the Treatment of up to Two De Novo Coronary Artery Lesions
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms PLATINUM-WH
- 02 Nov 2017 4-Year Clinical Outcomes in PLATINUM-like patients from PE Plus PAS, PE PROVE and PLATINUM studies (n=1907) presented at the 29th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics
- 02 Feb 2017 Status changed from active, no longer recruiting to completed.
- 14 Jan 2014 Results published in the American Journal of Cardiology.